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The epidermal growth factor (EGF) is one of the most important
mitogens for many epithelial cells and typically promotes cell
proliferation through the well-characterized Grb2/SOS/Ras/Raf/
ERK pathway (Ullrich and Schlessinger, 1990). Recent studies
from several laboratories have shown that EGF can also act as a
survival factor in suppressing apoptosis induced by various death
signals (Caraglia et al, 1999; Gibson et al, 1999; Lan and Wong,
1999; McClellan et al, 1999; Payne et al, 1999; Leu et al, 2000).
This latter function is performed primarily by EGF receptor-
mediated activation of the phosphatidylinositol 3¢-OH kinase (PI-
3K) pathway and/or the mitogen-activated protein kinase (MAPK)
pathway. EGF activates PI-3K through EGF receptor-associated
substrate molecules, such as the Grb2-associated binder-1 (Gab1),
that form the docking sites for the SH2 domains of the p85 adapter
subunit of PI-3K. This recruits PI-3K to proximity with the EGF
receptor, enabling subsequent phosphorylation and activation of
PI-3K (Rodrigues et al, 2000). Additionally, EGF can also activate
PI-3K through the small guanosine triphosphatase (GTP)-binding
protein Ras, which interacts directly with the catalytic subunit of
PI-3K in a GTP-dependent manner through the Ras effector site
(Rodriguez-Viciana et al, 1994). Activation of PI-3K leads to acti-
vation of a serine/threonine kinase termed protein kinase B (PKB)
or Akt (Downward, 1998), which promotes cell survival by phos-
phorylating and inactivating several key apoptosis regulatory
molecules, including the pro-apoptotic bcl-2 family member Bad 
(Datta et al, 1997; del Peso et al, 1997), the protease caspase-9
(Cardone et al, 1998), and the forkhead transcription factor
FKHRL1 (Brunet et al, 1999). In contrast to PI-3K, MAPK is
traditionally considered to be a component of the Grb2/SOS/
Ras/Raf/ERK protein kinase cascade, linking growth and differen-
tiation signals with transcription in the nucleus. Activated MAPK
(ERK p44/p42) translocates to the nucleus, where it activates tran-
scription by phosphorylation of such transcription factors as Elk-1
and stat3. Recent studies suggested that MAPK is also involved in
cell survival. Phosphorylation of Bad at either Ser-136 and Ser-
112 promotes the binding of Bad to 14-3-3 protein and inhibits the
binding of Bad to the pro-survival proteins Bcl-X and Bcl-2 (Zha
et al, 1996). While Akt phosphorylates Bad at Ser-136, recent
studies demonstrated that the MAPK-activated p90 ribosomal S6
kinase family (Rsks) phosphorylates Bad at Ser-112 (Bonni et al,
1999; Fang et al, 1999; Scheid et al, 1999). The results of these
studies provided an important convergence of the Grb2/SOS/
Ras/Raf/MEK/ MAPK/Rsk pathway and the PI-3K/Akt pathway
in promoting cell survival. 
We herein report our observations that EGF acts as a survival
factor in inhibiting paclitaxel-induced apoptosis in SiHa human
cervical cancer cells through a PI-3K- or MAPK-independent
pathway. We found that the anti-apoptotic effect involves the EGF-
activated c-Jun NH2-terminal kinase (JNK) pathway but not the
PI-3K/Akt or MEK/MAPK signalling pathway in the cells. The
JNK pathway is homologous to MAPK in its overall pathway but
is activated largely by distinct extracellular stimuli, such as ultra-
violet irradiation, osmotic stress, DNA-damaging agents, inflam-
matory cytokines and even growth factors (Ichijo, 1999; Leppa
and Bohmann, 1999). EGF can activate the JNK signalling
pathway in certain cell types (Hashimoto et al, 1999; Chen et al,
2000). In contrast to EGF-mediated MAPK activation, which was
abolished upon the loss of the Grb2 adapter protein but not upon
the loss of the Shc adaptor protein, EGF-mediated JNK activation
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Activation of JNK phosphorylates the N-terminal domain of the
transcription factor c-Jun, thereby increasing its transactivation
potency. Although there is compelling evidence that c-Jun activa-
tion can lead to apoptosis (Zanke et al, 1996; Tournier et al, 2000),
a number of reports indicate that, under certain circumstances,
activation of c-Jun can also inhibit apoptosis and promote cell
proliferation, transformation, or differentiation (Nishina et al,
1997; Smith et al, 1997). In addition, many studies also report a
lack of correlation between JNK activation and apoptosis (Liu 
et al, 1996; Khwaja and Downward, 1997). Thus, it is apparent
that the effects of c-Jun activation on cellular response depend on
cell types and the context of other regulatory signals that the cells
receive from the environment. The results of our current studies
indicate that activation of JNK by EGF protected SiHa cervical
cancer cells from paclitaxel-induced apoptosis. 
MATERIALS AND METHODS 
Cell lines and tissue culture 
SiHa human cervical cancer cells and MDA-MB-468 breast
cancer cells were obtained from American Type Culture
Collection (Manassas, VA, USA). The cells were maintained in
1:1 (v/v) Dulbecco’s modified Eagle medium/Ham’s F-12 mixture
supplemented with 10% fetal bovine serum (FBS) in a 37˚C
humidified atmosphere containing 95% air and 5% CO2. 
Antibodies and reagents 
Anti-HA monoclonal antibody was obtained from Roche
Diagnostics Corp (Indianapolis, IN, USA). Anti-phosphotyrosine
monoclonal antibody (4G10) was purchased from Upstate
Biotechnology Inc (Lake Placid, NY, USA). Anti-phosphorylated
Akt polyclonal antibodies (Ser473 and Thr308), anti-Akt poly-
clonal antibody, anti-phosphorylated p44/p42 MAPK monoclonal
antibody, anti-phosphorylated JNK polyclonal antibody, anti-
phosphorylated p38 MAPK polyclonal antibody, and anti-p38
MAPK polyclonal antibody were purchased from New England
Biolabs, Inc (Beverly, MA, USA). Anti-ERK2 polyclonal anti-
body was from Santa Cruz Biotechnology, Inc (Santa Cruz, CA,
USA), anti-JNK1 monoclonal antibody (G151–333) was from
PharMingen Biotechnology, Inc (San Diego, CA, USA) and anti-
poly-(ADP-ribose) polymerase (PARP) antibody C-2-10 was
purchased from CHUL Research Center, Laval University
(Quebec, Canada). Paclitaxel (Taxol) was purchased from Bristol-
Myers Squibb Company (Princeton, NJ, USA). Recombinant EGF
was obtained from Collaborative Research Inc. (Bedford, MA,
USA). PD98059, LY294002, and SB202190 were obtained from
CalBiochem Corp (San Diego, CA, USA). Protein A-sepharose
beads used for immunoprecipitation were purchased from
Repligen Corp (Cambridge, MA, USA). All other reagents were
purchased from Sigma Chemical (St. Louis, MO, USA) unless
otherwise specified. 
Quantification of apoptosis by ELISA 
We used an apoptosis ELISA kit (Roche Diagnostics Corp) to
quantitatively measure cytoplasmic histone-associated DNA frag-
ments (mononucleosomes and oligonucleosomes) after induced
cell death. This photomeric enzyme immunoassay was performed
according to the manufacturer’s instructions. 
Caspase-3 enzymatic activity assay 
Caspase-3 enzymatic activities were measured by colorimetric
assays with a kit purchased from Clontech Laboratories, Inc (Palo
Alto, CA, USA). The assay is based on spectrophotometric detec-
tion of the chromophore p-nitroanilide (pNA), which is cleaved
from the caspase-3 specific substrate DEVD-pNA by activated
caspase-3. The assay was performed according to the manufac-
turer’s instructions. 
Transfection of cells with expression vectors 
Cell transfection was performed with the FuGENETM-6 transfec-
tion kit (Roche Diagnostic Corp) according to the manufacturer’s
instructions. 
Western blot analysis 
Cells were lysed in a lysis buffer containing 50 mM Tris (pH 7.4),
150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, 25 mg ml–1 leupeptin, and
25 mg ml–1 aprotinin. The lysates were cleared by centrifugation,
and the supernatants were collected. Equal amounts of lysate
protein were used for Western blot analysis with the indicated
antibodies as previously described (Fan et al, 1995). 
PI-3K activity assay 
The PI-3K activity assay was performed as previously reported
(Lu et al, 1996). Briefly, equal amounts of cell lysate were
subjected to immunoprecipitation with anti-phosphotyrosine
monoclonal antibody 4G10. The immunoprecipitates were resus-
pended in 60 ml of kinase buffer containing 33 mM Tris-HCl (pH
7.6), 125 mM NaCl, 15 mM MgCl2, 200 mM adenosine, 20 mM
ATP, and 30 mCi of [g-32P]ATP (New England Nuclear, Boston,
MA, USA). PI-3K assays were initiated by the addition of 10 ml of
PI suspension to the immunoprecipitates. The reaction was
allowed to proceed for 30 min at room temperature and was termi-
nated by the addition of 100 ml of 1 N HCl to the reaction mixture.
Lipids were extracted with 600 ml of chloroform-methanol (1:1)
and separated by thin-layer chromotography with chloroform-
methanol-ammonium hydroxide-distilled water (60:47:2:11.3).
Radiolabelled PIP was visualized by autoradiography. 
JNK1 and p38 kinase activity assay 
The JNK1 and p38 kinase assay was performed as previously
described (Liu et al, 2000). Briefly, equal amounts of cell lysate
were subjected to immunoprecipitation with anti-JNK1 mono-
clonal antibody or anti-p38 antibody. The immunoprecipitates
were washed twice with a kinase buffer (20 mM Tris, 7.5 mM
MgCl2, 1 mM dithiothreitol). The kinase reaction was performed
by incubating the immunoprecipitates with 40 ml of kinase buffer
containing 2 mg of GST-c-Jun (or GST-ATF2), 25 mM lithium
ATP, and 5 mCi of [g-32P]ATP at 30˚C for 30 min. The reaction was
terminated by boiling the samples with 40 ml of 2x SDS sample
buffer. The products of the reaction were resolved using 10%
SDS-PAGE and then subjected to autoradiography. 
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Inhibition of paclitaxel-induced apoptosis by EGF in
SiHa cells 
SiHa cells are sensitive to treatment with paclitaxel. A 4-h pulse
exposure of the cells to paclitaxel caused the cells to undergo
apoptosis 16 to 24 h later, as measured by an apoptosis ELISA
(Figure 1A). The induction of apoptosis was paclitaxel dose-
dependent and was most pronounced in the dose range from 0.01
to 10 mM paclitaxel (Figure 1B). The apoptosis was characterized
by an elevated level of caspase-3 activity and by cleavage of the
caspase-3 substrate PARP (Figure 1C). When EGF was added
during the post-paclitaxel period, the induction of apoptosis was
markedly reduced (Figure 2A). The inhibition of paclitaxel-
induced apoptosis by EGF was accompanied by a lower level 
of caspase-3 activity and a lower rate of cleavage of PARP 
(Figure 2B and inset). 
Lack of involvement of the PI-3K/Akt and MEK/MAPK
pathways in EGF-mediated protection against
paclitaxel-induced apoptosis 
Because EGF activates the PI-3K/Akt and MEK/MAPK pathways
in a variety of human cell types, to learn how EGF protects SiHa
cells from paclitaxel-induced apoptosis, we first examined
whether EGF activated one or both of these pathways. Figure 3
shows that SiHa cells contain a high basal level of phosphorylated
MAPK and a high level of total ERK protein. In contrast with the
results observed in a control cell line, MDA-MB-468 human
breast cancer cells, that EGF stimulated phosphorylation of
MAPK p44/p42, stimulation of SiHa cells with EGF under similar
condition did not increase the MAPK phosphorylation. Figure 4A
Inhibition of paclitaxel-induced apoptosis by EGF through JNK 305
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Figure 1 Induction of apoptosis and activation of caspase-3 by paclitaxel in
SiHa cells. SiHa cells were pulse-exposed to 1 mM paclitaxel for 4 h followed
by additional indicated hours of post-paclitaxel period in culture medium
containing 0.5% FBS (A), or were pulse-exposed to serially diluted doses of
paclitaxel for 4 h, followed by a 20-h post-paclitaxel period in culture medium
containing 0.5% FBS (B and C). Cells were then harvested and subjected to
an apoptosis ELISA analysis (A and B) or caspase-3 assay (C) as described
in Materials and Methods. Inset: Cleavage of the capsase-3 substrate PARP
by paclitaxel treatment. Cell lysates were separated by SDS-PAGE, followed
by Western blot analysis with antibodies against PARP and b-actin 
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Figure 2 Inhibition of paclitaxel-induced apoptosis and activation of
caspase-3 by EGF in SiHa cells. SiHa cells were exposed to 1 mM paclitaxel
for 4 h, followed by an additional 20-h post-paclitaxel culture period with
increasing concentrations of EGF, in culture medium containing 0.5% FBS.
Cells were then harvested and subjected to an apoptosis ELISA analysis (A)
or caspase-3 assay (B) as described in Materials and Methods. Inset:
Inhibition of paclitaxel-induced capsase-3 substrate PARP cleavage by EGF.
Cell lysates were separated by SDS-PAGE, followed by Western blot
analysis with antibodies against PARP and b-actin shows the results with a PI-3K activity assay. Again, in contrast to
the results for MDA-MB-468 cells, in which EGF activated PI-3K
(as shown by increased phosphorylation of phosphatidylinositols
after EGF stimulation), SiHa cells exhibited a high basal level 
of PI-3K activity, and stimulation of these cells with EGF did 
not increase the level of phosphorylated phosphatidylinositols. 
In the MDA-MB-468 cells, Western blot analysis with anti-
phosphorylated Akt antibodies (Ser473 or Thr308) showed a
time-dependent phosphorylation of Akt upon EGF stimulation.
Despite the high basal level of PI-3K activity, the level of phos-
phorylated Akt was minimal in SiHa cells, even though the cells
did display a significant level of total Akt protein shown as a
doublet band on the SDS-electrophoresis pattern (Figure 4B).
Western blot analysis with an Akt2 specific antibody indicated
that the lower band of the Akt doublet was in same position as
Akt2, suggesting that it is likely to represent Akt2 (data not
shown). The observation that stimulation of SiHa cells with EGF
did not produce any detectable change in phosphorylated Akt on
serine-473 or threonine-308 suggests that there might be a defect
in the signal transduction pathway leading to phosphorylation of
Akt upon PI-3K activation in SiHa cells, which is beyond the
scope of current study. Taken together, these results indicate
that EGF does not stimulate the PI-3K/Akt and MEK/MAPK
pathways in SiHa cells. 
The PI-3K-specific inhibitor LY294002 and the MEK-
specific inhibitor PD98059 have been extensively used in litera-
ture for their respective specific effects on these two pathways
(Vlahos et al, 1994, 1995; Dudley et al, 1995; Langlois et al,
1995; Waters et al, 1995; Yano et al, 1995; Baumann and West,
1998; Cardone et al, 1998; Kultz et al, 1998). To exclude
whether any basal activities of PI-3K/Akt and MEK/MAPK were
involved in EGF-mediated protection against paclitaxel-induced
apoptosis, we investigated whether these two inhibitors could
interfere with this protection. Figure 5A shows that the pacli-
taxel-induced apoptosis was strongly inhibited by EGF (Figure
5A, bars 5 and 6). Co-exposure of the cells to EGF and
LY294002 (bar 7) or PD98059 (bar 8) had only a moderate effect
on EGF-mediated inhibition of paclitaxel-induced apoptosis. To
further confirm this result, we examined the effects of transient
expression of dominant-negative MEK cDNA (MEK-DN) or
dominant-negative PI-3K (∆ p85) on the EGF-mediated inhibi-
tion of paclitaxel-induced apoptosis. Both MEK-DN and PI-3K
∆ p85 were expressed in SiHa cells after the transient transfection
(Figure 5B, inset). In our studies, transfection of the cells with an
expression vector containing GFP cDNA under similar experi-
mental conditions resulted in 35–50% of the cells being GFP
positive (green cells) (data not shown). Neither the expression of
MEK-DN nor the expression of PI-3K ∆ p85 reversed the protec-
tive effect of EGF against paclitaxel-induced apoptosis in the
SiHa cells (Figure 5B). 
Involvement of JNK activity in the EGF-mediated
protection against paclitaxel-induced apoptosis 
JNK plays a dual role in the regulation of apoptosis. Recent studies
have shown that JNK can be involved in both the induction and
suppression of apoptosis in response to a variety of death signals
(Leppa and Bohmann, 1999). Because EGF can activate JNK
under some circumstances (Hashimoto et al, 1999; Chen et al,
2000), we therefore examined whether EGF activated JNK and the
related p38 MAPK in SiHa cells. We found that exposure of SiHa
cells to EGF resulted in a transient enhanced phosphorylation of
both JNK1 and JNK2, which peaked around 10 min after EGF
stimulation and disappeared 1 to 2 h after EGF stimulation (Figure
6A). There was no change in the level of JNK1 protein upon EGF
stimulation. We further confirmed this result with an in vitro
kinase assay using GST-Jun fusion protein as a substrate to
measure immunoprecipitated JNK1 activity following EGF treat-
ment in SiHa cells. In contrast to the results obtained with JNK
activation, EGF only marginally affected p38 MAPK phosphory-
lation and did not change its expression level in the cells (Figure 6B).
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Figure 3 Effect of EGF on activation of MEK/MAPK in SiHa cells. SiHa
and MDA-MB-468 cells were untreated or treated with 5 nM EGF for 10 and
30 min. Cells were then harvested, lysed, and subjected to Western blot
analyses with antibodies against phosphorylated MAPK p44/p42 and total
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Figure 4 Effect of EGF on activation of PI-3K/Akt in SiHa cells. A, SiHa and
MDA-MB-468 cells were untreated or treated with 5 nM EGF for 10 and
30 min. Cells were then harvested, lysed, and subjected to immuno-
precipitation with the anti-phosphotyrosine monoclonal antibody 4G10. The
immunoprecipitates were assayed for PI-3K activity with phosphatidylinositol
(PI) as a substrate as described in Materials and Methods. The bar graph
underneath shows quantitative determination (using arbitrary units) of PIP
production by phosphoimaging analysis. B, SiHa and MDA-MB-468 cells
were treated as described in (A). Cell lysates were prepared and subjected
to Western blot analysis with antibodies against ser473-phosphorylated Akt1,
thr308-phosphorylated Akt1, and total Akt protein, respectively An in vitro kinase assay using GST-ATF2 fusion protein as a
substrate showed no change in the phosphorylation level of GST-
ATF2 following EGF treatment in SiHa cells. 
To determine whether the JNK activation contributed to the
EGF-mediated protection against paclitaxel-induced apoptosis, we
examined whether selective inhibition of the JNK pathway with
the pyridinyl imidazole compound SB202190 would reverse the
protection. SB202190 was initially identified as a specific
inhibitor for p38 MAPK (Lee et al, 1994) but recent studies have
indicated that SB202190 also blocks activation of the JNK
pathway (Chen et al, 1998; Ming et al, 1998). Thus, we first 
examined whether SB202190 could block JNK activation induced
by ultraviolet irradiation in SiHa cells. We found that SB202190
clearly inhibited the activities of JNK1 and JNK2 in an
SB202190 dose-dependent manner (Figure 7A). There was no
change in the level of JNK1 protein upon ultraviolet irradiation
and SB202190 treatment. An in vitro kinase assay with GST-Jun
fusion protein as a substrate showed similar result of JNK
activity inhibition by SB202190. We then examined the effect of
SB202190 on EGF-induced activation of JNK and EGF-medi-
ated protection against paclitaxel-induced apoptosis in the cells.
Pretreatment of SiHa cells with 20 mM SB202190 inhibited EGF-
induced JNK1 activation at both the 10-min and 30-min time points
(Figure 7B). Pre-exposure of SiHa cells to 20 mM SB202190 almost
completely reversed the protective effect of EGF (Figure 7C). The
reversal of EGF-mediated protection against paclitaxel-induced
apoptosis by SB202190 was accompanied by restoration of
caspase-3 activity and cleavage of the caspase-3 substrate PARP
(Figure 7D and 7E). Because EGF did not activate p38 MAPK in
SiHa cells (Figure 6B), our results therefore strongly suggest that
JNK activation is involved in the EGF-mediated inhibition of pacli-
taxel-induced apoptosis in SiHa cells. 
DISCUSSION 
In this article, we report our results elucidating the signal pathways
by which EGF protects SiHa cervical carcinoma cells from 
paclitaxel-induced apoptosis. In contrast to its well-documented
Inhibition of paclitaxel-induced apoptosis by EGF through JNK 307
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in EGF-mediated protection from paclitaxel-induced apoptosis in SiHa cells.
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(control), 5 nM EGF, 2 mM LY 294002, or 10 mM PD 98059; in the right 4
bars, SiHa cells were pulse-exposed to 1 mM paclitaxel for 4 h, followed by a
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plus 2 mM LY 294002, or 5 nM EGF plus 10 mM PD 98059, as indicated.
Cells were harvested and subjected to an apoptosis ELISA analysis. B, SiHa
cells were transiently transfected for 30 h with a control vector, an HA-tagged
MEK dominant-negative (MEK-DN) vector, or an HA-tagged PI-3K dominant-
negative (∆p85) vector. During the last 4 h of the transfection, cells were
pulse-exposed to 1 mM paclitaxel. The cells were then cultured for an
additional 20-h post-paclitaxel period in the absence or presence of 5 nM
EGF, in 0.5% FBS medium. Cells were harvested and subjected to an
apoptosis ELISA analysis. Inset: Expression of PI-3K dominant-negative
vector (∆p85) and MEK dominant-negative vector (MEK-DN). After the
plasmids were removed from the culture medium, the cells were either
harvested immediately (0 h) or cultured for additional hours in regular culture
medium. Equal amounts of lysate protein from each sample were subjected
to Western blot analysis for the expression of MEK-DN or ∆p85 with anti-HA
or b-actin antibody 
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Figure 6 Activation of JNK but not p38 MAPK by EGF in SiHa cells.
A, SiHa cells were untreated or treated with 5 nM EGF for the indicated time
intervals. Cells were then harvested, lysed, and subjected to Western blot
analysis with antibodies that recognize phosphorylated isoforms of all 3
JNKs, and antibodies that specifically recognize JNK1, and then subjected to
an in vitro JNK1 kinase assay using GST-Jun as a substrate, as described in
Materials and Methods. B, SiHa cells were untreated or treated with 5 nM
EGF for the indicated time intervals. Cells were then harvested, lysed, and
subjected to Western blot analysis with antibodies against phosphorylated
p38 MAPK and total p38 MAPK and then subjected to an in vitro p38 kinase
assay using GST-ATF2 as a substrate, as described in Materials and
Methods activation of PI-3K/Akt or MEK/MAPK pathways in other cells,
EGF inhibited apoptosis in SiHa cells through a mechanism that
involves JNK activity. Overall, whether or not the JNK pathway
operates as a major EGF-mediated protective pathway in human
cancer seems cell type-dependent which is apparently the case in
SiHa cells. We speculate that it may exist as a backup pathway in
parallel with the MAPK and Akt pathways in some types of cells
or under certain circumstances. 
SiHa cells have low EGF receptor density compared with other
squamous carcinoma cell lines such as A431, HN5 or Caski. We
found that SiHa cells appear defective in Akt phosphorylation
following stimulation of the cells with EGF. The reasons why EGF
failed to stimulate PI-3K in SiHa cells and why the high basal level
of PI-3K was accompanied only by minimal level of Akt phospho-
rylation were not explored in current study, because this would
deviate from our focus. The lack of effect of EGF stimulation on
308 B Liu et al 
British Journal of Cancer (2001) 85(2), 303–311 © 2001 Cancer Research Campaign
EGF -- + - ++
Paclitaxel -- -+++
SB202190 - + ---+
EGF -- + - ++
Paclitaxel -- -+++
SB202190 - + ---+
0
0.4
0.8
1.2
1.6
I
n
d
u
c
t
i
o
n
 
o
f
 
a
p
o
p
t
o
s
i
s
(
O
.
D
.
 
@
 
4
0
5
 
n
m
)
C
a
s
p
a
s
e
-
3
 
a
c
t
i
v
i
t
y
(
O
.
D
.
 
@
 
4
0
5
 
n
m
)
0
1.0
1.5
2.0
C
E
D
P JNK 2 -
P JNK 1 -
JNK 1
GST-Jun
b-actin
C
o
n
t
r
o
l
0 1.25 5 20 40 SB202190
(20 mM)
EGF (5 nM)
UV
+
SB202190 (mM)
AB
-- - ++
- + + + +
Paclitaxel
EGF
--- + ++
SB202190 - + -- - +
- - - + + +
10 min 30 min
PARP
P JNK 2 -
P JNK 1 -
JNK 1
GST-Jun
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phosphorylated JNK and total JNK1 and subjected to an in vitro JNK1 kinase assay using GST-Jun as a substrate, as described in Materials and Methods. B,
Inhibition of EGF-activated JNK1 by SB202190. Cells were pretreated with 20 mM SB202190 for 1 h, followed by stimulation of the cells with 5 nM EGF for 10
and 30 min. Cell lysates were prepared and analysed as described in (A). C, D and E, Reversal of EGF-mediated inhibition of apoptosis by SB202190. SiHa
cells were exposed to 1 mM paclitaxel for 4 h, followed by an additional 20-h post-paclitaxel culture period in the absence or presence of 5 nM EGF or of 5n M
EGF plus 20 mM SB202190, as indicated. Cell lysates were prepared and subjected to an apoptosis ELISA analysis (C), caspase-3 activity assay (D), or
Western blotting analysis with antibodies directed against PARP and b-actin (E) PI-3K/Akt could be due to low expression of HER3 in these cells
(data not shown), which is generally believed to be a necessary
intermediate to couple the EGF receptor to this pathway. The
failure of Akt phosphorylation in the cells could be due to a possi-
bility that the kinases that phosphorylate Akt at threonine 308 and
serine 473 (PDK1 and PDK2, respectively) are defective.
Alternatively SiHa cells might express mutated Akt proteins that
can not be phosphorylated by PDK1 and PDK2. In addition to
having an abnormality in the PI-3K/Akt pathway, the SiHa cells
did not show a typical response to EGF-mediated activation of
MAPK either, although the proliferation of SiHa cells was stimu-
lated by EGF. Our as-yet-unpublished results indicate that EGF
appears to stimulate SiHa cell proliferation through a mechanism
that is independent of cyclin-dependent kinase activity (Schmidt
and Fan, manuscript in review). Inducible expression of p16Ink4a,
p21Waf1 or p27Kip1 in these cells, although strongly inhibiting CDK
activity, could not override the stimulatory effect of EGF on cell
proliferation, presumably because of the HPV16 infection status in
these cells. The HPV viral oncoprotein E7 has been shown to
render cells capable to bypass G1 arrest induced by serum depri-
vation and by p21Waf1, because the E7 protein constitutively
inactivates the Rb protein and causes sequestration of Rb from
E2F binding (Morozov et al, 1997). 
After we determined that the PI-3K/Akt and MEK/MAPK path-
ways were not involved, we examined the possible involvement of
the JNK pathway and found that the mechanism by which EGF
protected SiHa cells from paclitaxel-induced apoptosis was sensi-
tive to inhibition of JNK activity by SB202190. Although EGF did
not increase the activity of p38 MAPK (Figure 6B), our results
shown in Figure 6B do not exclude a possible requirement of some
basal activity of p38 MAPK for EGF-mediated protection against
paclitaxel-induced apoptosis, because the dose of SB202190 used
to inhibit JNK1 activity (Figure 6A) can also inhibit the basal
activity of p38 MAPK (Ming et al, 1998). 
The PI-3K pathway has been implicated in the activation of the
JNK signalling pathway (Klippel et al, 1996; Logan et al, 1997). In
these previous studies, EGF activated JNK1 in the HPV18-
positive HeLa human cervical cancer cell line, and this activation
was blocked by treatment of the cells with the PI-3K inhibitor
wortmannin and by transfection of the cells with a PI-3K domi-
nant-negative expression vector, suggesting that PI-3K played a
role in EGF-induced JNK activation in HeLa cells. Similarly, over-
expression of a truncated EGF receptor, EGFRvIII, transformed
NIH3T3 cells, accompanied by constitutive activation of PI-3K
and JNK1, with no increase in Ras/GTP levels and with low levels
of MAPK activity (Huang et al, 1997; Antonyak et al, 1998;
Moscatello et al, 1998). This constitutive JNK activity was down-
regulated following treatment of the cells with the PI-3K specific
inhibitor LY294002 (Treisman, 1996). The results of our current
study, however, suggest that EGF-induced JNK activation is 
PI-3K-independent. Previous studies have also shown that, in
addition to PI-3K, Ras and the Ras-related Rac/Rho small GTP-
binding proteins can also mediate EGF-induced JNK activation
(Su and Karin, 1996). EGF-mediated JNK activation was inhibited
by dominant negative Ras (RasN17) and dominant negative Rac1
(Rac1N17) (Wood et al, 1992; Susin et al, 1999). There are at least
two possible signalling pathways by which the EGF receptor can
activate Ras: one is the direct binding of the Grb2/SOS/Ras
complex to the phosphorylated EGF receptor (Li et al, 1993;
Batzer et al, 1994), and the other pathway involves the Shc adaptor
protein (Shc/Grb2/SOS/Ras) (Rozakis-Adcock et al, 1992; Gotoh
et al, 1995). Our observation that EGF activated JNK activity in
the SiHa cells without affecting the activities of PI-3K, ERK and
p38 MAPK suggests that JNK activation by EGF in SiHa cells
might involve, although not necessarily, the Shc adaptor protein.
The mechanism by which JNK-mediated pathway inhibits
paclitaxel-induced apoptosis in SiHa cells may partially involve
enhanced degradation of p53, because inhibition of EGF-induced
JNK activation with the JNK inhibitor SB202190 was accompa-
nied by reduced degradation of p53 and reduced inhibition of the
paclitaxel-induced apoptosis by EGF (data not shown). In addi-
tion, inhibition of p53 degradation in SiHa cells with the 26S
proteasaome inhibitor MG132 could partially reverse paclitaxel-
induced apoptosis (data not shown). It is known that EGF can acti-
vate AP-1, which is a collection of dimeric sequence-specific
transcriptional factors composed of c-Jun and c-Fos, in SiHa cells
and that AP-1 can bind to the enhancer region of HPV E6/E7
genes, thereby increasing the levels of HPV E6 and E7 expression
(Peto et al, 1995). Increased expression of E6 would then result in
increased binding to the E6-associated protein (E6-AP), and the
complex would tightly associate with p53, leading to rapid 
degradation of p53 via a ubiquitin proteasome-dependent pathway
(Scheffner et al, 1990; Crook et al, 1991). Unfortunately, we were
not able to detect E6 protein with Western blot analysis in our
study, presumably because of the very low concentrations of E6
protein produced by the naturally infected virus in SiHa cells.
Previous studies used Northern blot analysis to measure changes 
in the HPV E6/E7 mRNA level in HPV-infected cells. HPV E6/E7
protein was detected by Western blot analysis only in HPV 
E6/E7 cDNA-transfected cells. 
As it was mentioned in the introduction, JNK1 appears to play a
critical role in paclitaxel-induced apoptosis in several cellular
systems. Paclitaxel activates ASK1/JNK1, Raf/MAPK and p38
MAPK that may contribute to Bcl2 phosphorylation and release of
Bax resulting in apoptosis in these cellular systems (Stone and
Chambers, 2000; Subbaramaiah et al, 2000). These results appear
to contradict our results in the current study; however, there are
clearly JNK-independent mechanisms by which paclitaxel induces
apoptosis (Wang et al, 1999). SiHa cervical carcinoma cells, due to
the presence of HPV E6 and EGF-induced enhancement of E6
expression and subsequent degradation of p53, may represent a
different paradigm, wherein, JNK1-dependent p53 degradation
through JNK1/AP-1/E6/p53 plays a dominant role in determining
whether the cells undergo apoptosis. The result suggests that JNK1
may play different roles in paclitaxel-induced apoptosis in
different cell lineages. 
In summary, we demonstrated that the JNK signalling pathway
plays an important role in EGF-mediated protection from 
paclitaxel-induced apoptosis in the HPV E6-expressing SiHa cells.
Our data suggest that there could be clinical benefits from appro-
priate combination of conventional chemotherapeutic drugs with
new generation of signal transduction inhibitors. 
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